Seagen and Genmab Announce TIVDAK (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 4, 2023--
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Sep 4, 2023--